Upadacitinib, an anti-inflammatory drug commonly prescribed for rheumatoid arthritis, helped nearly half of patients with severe alopecia areata achieve significant scalp hair regrowth in two Phase 3 clinical trials, according to findings published in JAMA Dermatology. The trials, which included 1,399 participants aged 12 to 64 who had lost at least half of their scalp hair, evaluated daily doses of 15 milligrams, 30 milligrams, and a placebo over a 24-week period.
Clinical Trial Results and Dosage Efficacy
Researchers measured hair restoration using the Severity of Alopecia Tool, defining treatment success as achieving a score of 20 or less, which corresponds to at least 80% scalp hair coverage. According to the study data, 44.6 and 45.2 per cent of participants taking the 15-milligram dose reached this target across the two trials. Among those receiving the 30-milligram dose, success rates climbed to 54.3 and 55 per cent. By comparison, only 1.5 and 3.4 per cent of participants taking the placebo achieved the same level of regrowth.
Additional coverage from Medscape noted that patient responses continued to improve through one year of treatment. Furthermore, between 13 and 22.5 per cent of participants taking upadacitinib regained complete scalp hair coverage by 24 weeks, depending on the dosage and trial. Patients also exhibited noticeable improvements in eyebrow and eyelash growth, areas frequently impacted by the autoimmune condition.
Did you know? Alopecia areata affects an estimated 7 million Americans, according to the National Alopecia Areata Foundation, frequently developing at a young age and carrying significant psychological and emotional effects.
Mechanism of Action and Safety Profile
Alopecia areata occurs when the body’s immune system mistakenly attacks hair follicles, though the follicles typically remain undamaged, allowing hair to regrow once the immune attack stops. Upadacitinib operates as a Janus kinase, or JAK, inhibitor, blocking specific immune signals and inflammation pathways responsible for attacking the follicles.
While short-term safety results showed that serious side effects occurred in only a small proportion of participants, JAK inhibitors carry important medical warnings. Reported side effects during the trials included acne, upper respiratory infections, common colds, throat irritation, and elevated creatine phosphokinase levels. According to the sources, broader class risks for JAK inhibitors involve serious infections, certain cancers, cardiovascular events, blood clots, and mortality, meaning patients require medical supervision, screening, and regular monitoring.
Regulatory Status and Future Outlook
The drug is already approved by the FDA for several other inflammatory conditions, including rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
Study authors noted several limitations accompanying the trials. The research was funded and co-designed by AbbVie, the manufacturer of upadacitinib, and some investigators are company employees. Additionally, the trials lasted for 24 weeks, leaving questions regarding long-term safety and efficacy. Independent peer-reviewed research will be required to compare upadacitinib directly against existing alopecia treatments.
Frequently Asked Questions
What is upadacitinib?
Upadacitinib is an anti-inflammatory medication and Janus kinase (JAK) inhibitor marketed as Rinvoq, primarily used to treat inflammatory conditions like rheumatoid arthritis.
How does the drug help with hair loss?
By blocking specific immune signals and inflammation, upadacitinib stops the immune system from attacking hair follicles, allowing them to resume normal growth in patients with severe alopecia areata.
What are the main side effects of upadacitinib?
Commonly reported side effects in clinical trials include acne, upper respiratory infections, colds, throat irritation, and elevated creatine phosphokinase levels. JAK inhibitors also carry warnings for serious infections, blood clots, and cardiovascular risks.
Is upadacitinib approved for alopecia areata?
Food and Drug Administration.
Join the Conversation: What are your thoughts on expanding JAK inhibitor treatments for severe autoimmune conditions? Share your perspective in the comments below, explore our related health coverage, or subscribe to our newsletter for the latest clinical trial updates.
Related reading